Kristopher K Frese
Overview
Explore the profile of Kristopher K Frese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
4494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lallo A, Gulati S, Schenk M, Khandelwal G, Berglund U, Pateras I, et al.
Br J Pharmacol
. 2018 Nov;
176(3):436-450.
PMID: 30427531
Background And Purpose: Small cell lung cancer (SCLC) is an aggressive disease with median survival of <2 years. Tumour biopsies for research are scarce, especially from extensive-stage patients, with repeat...
12.
Blackhall F, Frese K, Simpson K, Kilgour E, Brady G, Dive C
Lancet Oncol
. 2018 Sep;
19(9):e470-e481.
PMID: 30191851
Small-cell lung cancer (SCLC) is an aggressive tumour that seeds metastases early with dismal outcomes. As expected from a disease that is closely associated with smoking, mutation burden in SCLC...
13.
Torres-Ayuso P, Sahoo S, Ashton G, An E, Simms N, Galvin M, et al.
NPJ Genom Med
. 2018 Jun;
3:15.
PMID: 29951225
Precision medicine aims to tailor cancer therapies to target specific tumor-promoting aberrations. For tumors that lack actionable drivers, which occurs frequently in the clinic, extensive molecular characterization and pre-clinical drug...
14.
Lallo A, Frese K, Morrow C, Sloane R, Gulati S, Schenk M, et al.
Clin Cancer Res
. 2018 Jun;
24(20):5153-5164.
PMID: 29941481
Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer (SCLC), a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to...
15.
Foy V, Schenk M, Baker K, Gomes F, Lallo A, Frese K, et al.
Lung Cancer
. 2017 Nov;
114:12-22.
PMID: 29173760
SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development of chemo-resistant disease, less than 5% of patients survive 5 years. Despite 3 decades of...
16.
Meehan T, Conte N, Goldstein T, Inghirami G, Murakami M, Brabetz S, et al.
Cancer Res
. 2017 Nov;
77(21):e62-e66.
PMID: 29092942
Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual...
17.
Lallo A, Schenk M, Frese K, Blackhall F, Dive C
Transl Lung Cancer Res
. 2017 Sep;
6(4):397-408.
PMID: 28904884
Lung cancers are the main cause of cancer-related deaths worldwide. Efforts placed to improve the survival of lung cancer patients and untangle the complexity of this disease, have resulted in...
18.
Khandelwal G, Girotti M, Smowton C, Taylor S, Wirth C, Dynowski M, et al.
Mol Cancer Res
. 2017 Apr;
15(8):1012-1016.
PMID: 28442585
Patient-derived xenograft (PDX) and circulating tumor cell-derived explant (CDX) models are powerful methods for the study of human disease. In cancer research, these methods have been applied to multiple questions,...
19.
Kaistha B, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, et al.
Cancer Res
. 2015 Dec;
76(1):96-107.
PMID: 26669866
Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumors and is generally strongly resistant to currently available chemo- and/or radiotherapy regimens, including targeted molecular therapies. Therefore,...
20.
Serrao E, Kettunen M, Rodrigues T, Dzien P, Wright A, Gopinathan A, et al.
Gut
. 2015 Sep;
65(3):465-75.
PMID: 26347531
Objectives: Pancreatic cancer (PCa) is treatable by surgery when detected at an early stage. Non-invasive imaging methods able to detect both established tumours and their precursor lesions are needed to...